Cladribine for untreated or early low-grade non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 30, Issue 5-6, 1998, Pages 573-581

  Liliemark, Jan ^a   Martinsson, Ulla ^b   Cavallin Ståhl, Eva ^c   Svedmyr, Erik ^a   Porwit, Anja ^a   Strömberg, Mats ^a   Juliusson, Gunnar ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

2 CdA; Cladribine; Intermittent infusion; Lymphoma; Phase II trial; Toxicity; Untreated

Indexed keywords

CHLORAMBUCIL; CLADRIBINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INFECTION COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031820075     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057569     Document Type: Article

References (31)

1. Christensen, L. F., Broom, A. D., Robins, M. J. and Bloch, A. (1972). Synthesis and biochemical activity selected 2,6-disubstituted-(2-deoxy-α- and β-D-erythro-pentofuranosyl)purines. J. Med. Chem., 15, 735-739.
2. Carson, D. A., Wasson, D. B. and Beutler, E. (1984). Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc. Natl. Acad. Sci., 2232-2236.
3. Santana, V. M., Hurwitz, C. A., Blakley, R. L., Crom, W. R., Luo, X., Roberts, W. M., Ribiero, R., Mahnoud, H. and Krance, R. A. (1994). Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood, 84, 1237-1242.
4. Sipe, J. C., Romine, J. S., Koziol, J. A., McMillan, R., Zyroff, J. and Beutler, E. (1994). Cladribine in treatment of chronic progressive multiple sclerosis. Lancet, 334, 9-13.
5. Piro, L. D., Carrera, C. J., Carson, D. A. and Beutler, E. (1990). Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New. Engl. J. Med., 322, 1117-1121.
6. Estey, E., Kurzrock, R., Kantarjian, H., O'Brian, S., McCredie, K., Beran, M., Koller, C., Keating, M., Hirsch-Ginsberg, C., Huh, Y. and Freireich, E. (1992). Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood, 79, 882-887.
7. Juliusson, G., Heldal, D., Hippe, E., Hedenus, M., Wallman, K., Malm, C., Stolt, C. M., Evensen, S. A., Tjønnfjord, G., Lenkei, R. and Liliemark, J. (1995). Subcutaneous injection of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J. Clin. Oncol., 13, 989-995.
8. Piro, L. D., Carrera, C. J., Beutler, E. and Carson, D. A. (1988). 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood, 72, 1069-1073.
9. Saven, A., Carrera, C. J., Carson, D., Beutler, E. J. and Piro, L. (1991). Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymph., 5 (Suppl). 133-138.
10. Juliusson, G. and Liliemark, J. (1992). High complete remission rate from 2-chloro-2′-deoxyadenosine (CdA) in previously treated patients with B-cell chronic lymphocytic leukemia; Response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol., 11, 679-689.
11. Liliemark, J., Porwit, A. and Juliusson, G. (1997). Intermittent infusion of cladribine in previously treated patients with low-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma, 25, 313-318.
12. Kay, A., Saven, A., Carrera, C., Carson, D., Thurston, D., Beutler, E. and Piro, L. (1992). 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol., 10, 371-377.
13. Morton, J., Taylor, K., Bunce, I., Eliadis, P., Rentoul, A., Moore, D., Kelly, C., Wright, S., Bashford, J., Rodwell, R., Rooney, K., Mulligan, S., Firhin, F., Doods, A., Parkin, J., Lowenthal, R., Kimber, R., Frost, T., Grigg, A., Goldstein, D., Stone, J. and Lee, N. (1996). High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Br. J. Haematol., 95, 110-115.
14. Bosly, A., Ferrant, A., Delannoy, A., Chatelain, P., Martiat, G., Cornu, G. and Doyen, C. (1993). 2-Chlorodeoxyadenosine therapy in non-Hodgkin's lymphoma. Blood, 10(suppl. 1), 560.
15. Liliemark, J., Hagberg, H., Cavallin-Ståhl, E. and Juliusson, G. (1994). Cladribine (2-CdA) for early low grade non-Hodgkin's lymphoma (LG-NHL). Blood, 84 (suppl), 168a.
16. Liliemark, J. and Juliusson, G. (1991). On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res., 51, 5570-5572.
17. Liliemark, J. and Juliusson, G. (1995). Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res., 1, 385-390.
18. Harris, N.L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J.K.C., Cleary, M. L., Delsol, G., Wolf-Peeters, C. D., Falini, B., Gatter, K. C., Grogan, T. M., Isacsson, P., Knowles, D., Mason, D., Muller-Heremlink, H., Pileri, S., Piris, M., Ralfkiear, E. and Warnke, R. (1994). A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood, 84, 1361-1392.
19. (1993). The international non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl. J. Med., 329, 987-994.
20. Green, S. and Weiss, G. (1992). Southwest oncology group standard response criteria, endpoint definitions and toxicity criteria. Investigational new drugs., 10, 239-253.
21. Saven, A., Lemon, R. H., Kosty, M., Beutler, E. and Piro, L. D. (1995). 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol., 13, 570-574.
22. Saven, A., Emanuele, S., Kasty, M., Koziol, J., Ellison, D. and Piro, L. (1995). 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood, 86, 1710-1716.
23. Betticher, D. C., Zucca, E., vonRohr, A., Egger, T., Radford, J. A., Ambrosetti, A., Bürki, K., Rufener, B., Schmitz, S. F. and Cerny, T. (1996). 2-chlorodeoxyadenosine (2-CDA) therapy in untreated patients with follicular stage III-1V non-Hodgkin's lymphoma. Ann. Oncol., 7, 793-799.
24. Piro, L. D., Petroni, G., Barcos, M., Johnson, J., Saven, A. and Peterson, B. (1995). Bolus infusion 2-chlorodeoxyadenosine (2CdA) as first line therapy of low-grade non-Hodgkin's lymphoma (NHL). Blood, 86 (suppl. 1), 274a.
25. Rummel, M., Mitrou, P. S., Leimer, L., Knuth, A., Schadeck-Gressel, C., Hossfeld, D., Bergmann, L. and Hoelzer, D. (1997). 2-Chlorodeoxyadenosine (2-CDA, cladribine) in the treatment of previously untreated low-grade non-Hodgkin's lymphomas - preliminary results of a phase II study. Proc. Am. Soc. Clin. Oncol., 16, 18a.
26. Kaufmann, T., Coleman, M. and Pasmantier, M. (1996). Purine analog (PA) therapy for untreated mantle cell (MCL) and monocytoid (MNL) lymphomas: immunophenotype does not predict response to fludarabine (FLUD) and cladribine (2CdA). Prc. Am. Soc. Clin. Oncol., 15, 1320.
27. Kimby, E., Björkholm, M., Gahrton, G., Glimelius, B., Hagberg, H., Johansson, B., Johansson, H., Juliusson, G., Järnmark, M. and Löfvenberg, E. (1994). Chlorambucil/ prednisolone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann. Oncol., 5 (suppl. 2), 67-71.
28. Cheson, B. D. (1995). Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol., 13, 2431-2448.
29. vandenNeste, E., Delannoy, A., Vandercam, B., Bosly, A., Ferrant, A., Mineur, P., Montfort, L., Martiat, P., Straetmans, N., Filleul, B. and Michaux, J. L. (1996). Infectious complications after 2-chlorodeoxyadenosine therapy. Eur. J. Haematol., 56, 235-240.
30. vonRohr, A., Betticher, D. C., Fey, M. F., Racine, C., Tobler, A. and Cerney, T. (1997). Treatment with combined 2-chlorodeoxyadenosine and interleukin-2 for low-grade B cell malignancies: a pilot study. Proc. Am. Soc. Clin. Oncol., 16. 18a.
31. Juliusson, G., Lenkei, R. and Liliemark, J. (1994). Flow cytometry of blood and bone marrow cels from patients with hairy cell leukemia. Phenotype of hairy cells and lymphocyte subsets following treatment with 2-chlorodeoxyadenosine. Blood, 83, 3672-3681.